Is S & U PLC A Better Buy Than GlaxoSmithKline plc?

Should you buy a slice of lending specialist, S & U PLC (LON: SUS), ahead of GlaxoSmithKline plc (LON: GSK)?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

2015 has been a superb year for investors in lending specialist S&U (LSE: SUS), with the company posting a rise of 22% in its share price. Part of the reason for this is an improving macroeconomic outlook and continued low interest rates, which are combining to give consumers increased confidence to borrow and spend.

Of course, many investors may be somewhat concerned about the medium term outlook for lenders such as S&U. That’s because, with interest rates set to rise, demand for loans may come under pressure and could see the company’s top and bottom lines weaken somewhat. However, today’s trading update from S&U shows that the business is performing well and is able to look ahead to further strong performance moving forward.

For example, S&U has reported that gross receivables in its motor finance division, Advantage Finance, have increased to £200m for the first time in the company’s history. And, while total transaction volumes for the half year to the end of July have fallen, recent strength means that they should reach a record level for the full year.

Meanwhile, S&U’s home credit business reported a fall in sales of 9% in the first half of the year. And, while its profitability is flat versus the same period of last year, the decision to sell the business for £83m appears to be a sound one, since growth prospects for the division appear to be somewhat limited. Furthermore, the sale should provide S&U with increased scope to become a more specialist and niche lender, which could have a positive impact on the company’s profit margins.

Looking ahead, S&U is expected to post strong growth numbers next year, with its bottom line forecast to rise by as much as 18%. The company’s valuation, though, does not appear to reflect this impressive growth rate, with S&U trading on a price to earnings growth (PEG) ratio of just 0.8, which indicates further share price gains are on the cards.

Clearly, S&U is heavily reliant on the performance of the UK economy and, while it appears to be worth buying at the present time, a company with far less correlation to the wider economic outlook could outperform it. In fact, pharmaceutical company GlaxoSmithKline (LSE: GSK) offers a very bright outlook for next year, with its earnings set to rise by around 12%. As with S&U, its share price does not appear to reflect such impressive growth potential, with it trading on a PEG ratio of just 1.4.

In addition, GlaxoSmithKline offers a higher dividend yield than S&U. It yields around 5.7%, while S&U has a current yield of 3.1% and, while interest rates may be set to rise, impressive dividend yields are likely to remain en vogue among investors over the medium term, which could push GlaxoSmithKline’s share price higher.

This, coupled with its hugely impressive pipeline that notably includes potential HIV treatments via is ViiV Healthcare subsidiary, as well as excellent growth, low correlation with the wider economy and a relatively appealing valuation, means that GlaxoSmithKline appears to be a better buy than S&U at the present time. Certainly, GlaxoSmithKline may be going through a transitional period but, for long term investors, this presents an opportunity to buy-in ahead of improved financial performance.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Empty Stocks and Shares ISA? I’d snap up these 3 stocks to start with!

Sumayya Mansoor explains how she would start to build wealth from scratch with an empty Stocks and Shares ISA and…

Read more »

Concept of two young professional men looking at a screen in a technological data centre
Investing Articles

7.7% yield and going cheap! Why is this unknown FTSE 250 stock flying?

It's no household name, but there's one FTSE 250 stock with a high dividend yield and booming profits that looks…

Read more »

Photo of a man going through financial problems
Investing Articles

I’d stop staring at the Nvidia share price and buy this FTSE 100 stock instead

This writer reckons there is a smarter way to invest in Nvidia today without taking on stock-specific risk. Here is…

Read more »

Young lady working from home office during coronavirus pandemic.
Top Stocks

5 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Young Asian man drinking coffee at home and looking at his phone
Dividend Shares

These 3 FTSE 250 stocks offer me the highest dividend yields, but should I buy?

Jon Smith considers FTSE 250 shares with a very high yield, but questions whether the income is going to be…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Is FTSE 100 takeover target DS Smith a great buy?

A mega-merger between FTSE 100 giants DS Smith and Mondi has the City abuzz. But is there any value in…

Read more »

Young Black man sat in front of laptop while wearing headphones
Investing Articles

The WPP share price dips as profits fall. Here’s why it could be a top dividend buy

I'm starting to think the WPP share price undervalues the stock, especially if the long-term dividend outlook comes good.

Read more »

Black father and two young daughters dancing at home
Investing Articles

A £3K investment buys me 632 shares in 2 stocks for a second income!

This Fool explains how a second income is possible through dividend-paying stocks and details two picks that could help her.

Read more »